Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.50 |
| ▸ | JAK2 | O60674 | 7/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405165 | 0.95 | FGFR1 (0.49) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL30405629 | 0.87 | JAK2 (0.54) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL14617314 | 0.84 | TGFBR1 (0.62) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL30405231 | 0.84 | TGFBR1 (0.62) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL23150464 | 0.82 | JAK3 (0.59) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL30405232 | 0.79 | MTOR (0.68) | TGFBR1ABL1LCKKCNH2 | |
| SCHEMBL17267749 | 0.79 | JAK2 (0.78) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL31046956 | 0.79 | TGFBR1 (0.64) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL23150533 | 0.78 | JAK2 (0.54) | JAK3JAK2JAK1FGFR1FGFR2 | |
| SCHEMBL17936188 | 0.78 | KCNH2 (0.56) | JAK3JAK2JAK1ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | JAK3 2053/4885JAK2 445/4885JAK1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.